Concepedia

Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation

Shreyaskumar Patel, Varsha Gandhi, Jan Jenkins, Nicholas Papadopolous, M. A. Burgess, Carl Plager, William Plunkett, Robert S. Benjamin

Journal of Clinical Oncology · 2001 · 245 citations · 17 references

DOI

Abstract

Given the limited therapeutic armamentarium for STS, the activity of gemcitabine is encouraging. Its potential for combination therapy in the salvage setting should be studied with pharmacologically guided fixed dose-rate infusion.

References

17

Cancer statistics, 2000

Robert T. Greenlee, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 2000 · 3.9K citations · Full text

, , +14

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +6

Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

Peng Huang, Sherri Chubb, Larry W. Hertel et al. · PubMed · 1991 · 884 citations

, , +9

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

James L. Abbruzzese, Ralf Grunewald, Elizabeth A. Weeks et al. · Journal of Clinical Oncology · 1991 · 757 citations

, , +12

Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

Volker Heinemann, Yi-Zheng Xu, Sherri Chubb et al. · Molecular Pharmacology · 1990 · 405 citations